Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03667300
Other study ID # 2016-08-144
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 16, 2017
Est. completion date May 14, 2019

Study information

Verified date September 2019
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this multi-center, randomized, double-blind, active-controlled, phase II non-inferiority study, we aimed to test the non-inferiority of evogliptin vs linagliptin in terms of reduction of albuminuria at week 24 from baseline in patients with type 2 diabetes having renal insufficiency.


Description:

This is a multi-center, randomized, double-blind, active-controlled, phase II non-inferiority study. Evogliptin (Trade name, Suganon) is a new, novel dipeptidyl peptidase-4 (DPP4) inhibitor which reveals a favorable results on glucose-lowering effect in patients with diabetes. However, its effect on renal function in patients with diabetes has been uncertained. To compare the effect of evogliptin and linagliptin on the reduction of albuminuria, we will recruit a total of 210 patients with Type 2 diabetes and renal insufficiency and allocate the participants into evogliptin group and linagliptin group with a ratio of 1:1 after radomization from 10 hospitals. After the oral administration of evogliptin 5mg per day or linagliptin 5mg per day for 24 weeks, the percent change of urine albumin-to-creatinine ratio (UACR) at Week 24 and at baseline will be measured as a primary endpoint. In addition, the percent changes of UACR, hemoglobin A1c, Cystatin-C, Nephrin, N-acetyl-beta-D-glucosaminidase (NAG), glycated albumin, estimated glomerular filtration rate (eGFR) between baseline and Week 12 or Week 24 will be studied as secondary endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 209
Est. completion date May 14, 2019
Est. primary completion date May 14, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Men and women aged 20 years or older diagnosed with type 2 diabetes.

- subjects having a level of glycated hemoglobin (HbA1c) 7.0% or more, and 10% or less.

- subjects having urine albumin to creatinine ratio (UACR) 30 ug/mg or more, and 3000 ug/mg or less.

- subjects having estimated glomerular filtration rate (eGFR) 30 or more.

- subjects who had taken angiotensin II receptor blocker(ARB) or angiotensin-converting enzyme(ACE) inhibitors for more than 4 weeks.

- subjects having body mass index (BMI) 20kg/m2 or more, 40 kg/m2 or less.

- subjects who entirely understood all the process of clinical study protocol and voluntarily take part in the study and agree to follow rule of the study.

Exclusion Criteria:

- subjects having type 1 diabetes, secondary diabetes, or gestational diabetes

- subjects who had a history of surgery of resection of more than a half length of stomach or intestine.

- subjects having more than three-fold higher levels of Aspartate Transaminase(AST) or Alanine Transaminase(ALT) than upper normal limit.

- subjects who had taken Dipeptidyl Peptidase4(DPP4)-inhibitor or glucagon-like peptide-1(GLP-1) analogue within 8 weeks prior to screening.

- subjects who had taken oral triple hypoglycemic agents within 8 weeks prior to screening

- subjects taking strong cytochrome P450 3A4(CYP3A4) inhibitors or strong cytochrome P450 3A4(CYP3A4) inducers

- subjects who are pregnants or breast feeding givers.

- subjects who are unsuitable for clinical trial participation based on clinical laboratory test results or other reasons (e.g. taking chemotherapy or radiation for treatment for cancers).

Study Design


Intervention

Drug:
Evogliptin
This group will take daily evogliptin 5mg per oral, not linagliptin.
Linagliptin
This group will take daily linagliptin 5mg per oral, not evogliptin

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary UACR percent change at Week 24 Percentage change in urine albumin-to-creatinine ratio (UACR) after 24 weeks compared to baseline (%) Week 24
Secondary UACR change at Week 24 (%) Change in urine albumin-to-creatinine ratio (UACR) after 24 weeks compared to baseline (%) Week 24
Secondary UACR change at Week 12 Change in urine albumin-to-creatinine ratio (UACR) after 12 weeks compared to baseline (mg/g Week 12
Secondary HbA1c change at Week 24 Change in glycated hemoglobin after 24 weeks compared to baseline Week 24
Secondary HbA1c change at Week 12 Change in glycated hemoglobin after 12 weeks compared to baseline Week 12
Secondary HbA1c less than 6.5% at Week 24 proportion of parcipitants having glycated hemoglobin less than 6.5% after 24 weeks Week 24
Secondary HbA1c less than 6.5% at Week 12 proportion of participants having glycated hemoglobin less than 6.5% after 12 weeks Week 12
Secondary HbA1c less than 7.0% at Week 24 proportion of participants having glycated hemoglobin less than 7.0% after 24weeks Week 24
Secondary HbA1c less than 7.0% at Week 12 proportion of participants having glycated hemoglobin less than 7.0% after 12 weeks Week 12
Secondary NAG (N-acetyl-ß-D-glucosaminidase) change at Week 24 Change in NAG (N-acetyl-ß-D-glucosaminidase) after 24 weeks compared to baseline (U/L) Week 24
Secondary NAG (N-acetyl-ß-D-glucosaminidase) change at Week 12 Change in NAG (N-acetyl-ß-D-glucosaminidase) after 12 weeks compared to baseline (U/L) Week 12
Secondary Cystatin-C change at Week 24 Change in urinary Cystatin-C after 24 weeks compared to baseline (mg/L) Week 24
Secondary Cystatin-C change at Week 12 Change in urinary Cystatin-C after 12 weeks compared to baseline (mg/L) Week 12
Secondary Nephrin change at Week 24 Change in Nephrin after 24 weeks compared to baseline (ug/g cr) Week 24
Secondary Nephrin change at Week 12 Change in Nephrin after 12 weeks compared to baseline (ug/g cr) Week 12
Secondary Glycated albumin change at Week 24 Change in Glycated albumin after 24 weeks compared to baseline (%) Week 24
Secondary Glycated albumin change at Week 12 Change in Glycated albumin after 12 weeks compared to baseline (%) Week 12
Secondary eGFR at Week 24 Change in estimated glomerular filtration rate based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method after 24 weeks compared to baseline (mL/min) Week 24
Secondary eGFR change at Week 12 Change in estimated glomerular filtration rate based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method after 12 weeks compared to baseline (mL/min) Week 12
See also
  Status Clinical Trial Phase
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Completed NCT04024332 - Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects Phase 1
Completed NCT02849964 - Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions N/A
Active, not recruiting NCT03672110 - Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen Phase 3
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01462136 - PK Study of ACHN-490 Injection in Renally Impaired Subjects Phase 1
Completed NCT01172431 - Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency Phase 4
Completed NCT00765830 - Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension) Phase 3
Completed NCT00770081 - Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) Phase 3
Completed NCT01545531 - Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance N/A
Terminated NCT00338455 - Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC Phase 2
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Completed NCT02894905 - A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 Phase 1
Completed NCT02894385 - Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201) Phase 1
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT03235375 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects Phase 1
Withdrawn NCT03329612 - Remote Ischemic Preconditioning in ACS Patients N/A
Recruiting NCT02578784 - DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis N/A